Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Multi-Center, Open-Label, Dose-Escalation, Prime and Boost Vaccination Evaluation of VRON-0200 Using Two Chimpanzee Adenoviral Vectors in Adult Participants with Chronic HBV Infection Who Are Currently Receiving HBV Nucleos(t)ide Reverse Transcriptase Inhibitors

Next Previous
X
Search
Trial Profile

A Phase 1b Multi-Center, Open-Label, Dose-Escalation, Prime and Boost Vaccination Evaluation of VRON-0200 Using Two Chimpanzee Adenoviral Vectors in Adult Participants with Chronic HBV Infection Who Are Currently Receiving HBV Nucleos(t)ide Reverse Transcriptase Inhibitors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elebsiran (Primary) ; VRON-0200 (Primary) ; Tobevibart
  • Indications Hepatitis B
  • Focus Adverse reactions; First in man
  • Sponsors Virion Therapeutics

    • Most Recent Events

    • 24 Sep 2024 Treatment arms increased from 4 to 6. Experimental: cohort 3a and cohort 3b with new drugs VIR-2218 and VIR-3434 added newly.
    • 24 Sep 2024 Planned number of patients changed from 48 to 56.
    • 24 Sep 2024 Planned End Date changed from 23 Jan 2025 to 30 Nov 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top